G Mathé
About
In The Last Decade
G Mathé
427 papers receiving 5.9k citations
Hit Papers
Peers
Comparison fields: 5 of 149
- Oncology 2.2k
- Immunology 1.6k
- Molecular Biology 1.4k
- Hematology 998
- Pathology and Forensic Medicine 779
Countries citing papers authored by G Mathé
This map shows the geographic impact of G Mathé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Mathé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Mathé more than expected).
Fields of papers citing papers by G Mathé
This network shows the impact of papers produced by G Mathé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Mathé. The network helps show where G Mathé may publish in the future.
Co-authorship network of co-authors of G Mathé
This figure shows the co-authorship network connecting the top 25 collaborators of G Mathé. A scholar is included among the top collaborators of G Mathé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Mathé. G Mathé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Medical ethics and/or ethical medicine | 2 |
| 2 | 12 | |
| 3 | 82 | |
| 4 | Vindesine in Leukemia and Non-hodgkin Lymphoma | 1 |
| 5 | Adjuvant therapies of the various primary tumors | 2 |
| 6 | Histopathologic sequence of events in adult mice undergoing lethal graft-versus-host reaction developed across H-2 and/or non-H-2 histocompatibility barriers. | 75 |
| 7 | Non-H-2 antigens can induce high GVH mortality in adult recipients of normal cells. | 20 |
| 8 | [Treatment of clinical stages I and II of Hodgkin's disease]. | 1 |
| 9 | How far are in vivo models of experimental medicine valid for human medicine? | 1 |
| 10 | Logistics of therapeutic trials: the example of cancerology. | 1 |
| 11 | [Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late]. | 3 |
| 12 | Démonstration de l'efficacité de l'immunothérapie active dans la leucémie aiguë lymphoblastique humaine. | 8 |
| 13 | Valeur de la rubidomycine dans le traitement de la maladie de Hodgkin. | 2 |
| 14 | Investigation on a test of histocompatibility for allogeneic grafts. 3. A study in man. | 5 |
| 15 | Essai de traitement de la leucemie de charlotte friend par la greffe de cellules hematopoietiques de donneurs isogeniques vaccines contre le virus. | 3 |
| 16 | Etude des agglutinines seriques contre un antigene bacterien chez des radiochimeres hematologiques immunisees contre l'antigene avant l'irradiation. | 3 |
| 17 | Etude en microscopie optique et electronique des 'cellules immunolo- giquement competentes' au cours des reactions de greffe. | 1 |
| 18 | Traitement de souris akr a l'age de six mois par irradiation totale suivie de transfusion de cellules hematopoietiques allogeniques. Incidences respectives de la leucemie et du syndrome secondaire. | 1 |
| 19 | [Transfusion and graft of bone marrow in man: technic]. | 0 |
| 20 | [Practical treatment of acute leukosis]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.